LSP
LSP is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at LSP.
LSP is a company.
Key people at LSP.
Key people at LSP.
Life Sciences Partners (LSP) is a leading European venture capital and private equity firm specializing in life sciences investments, now integrated into EQT following its acquisition.[1][3][6] Founded in 1988 and headquartered in the Netherlands, LSP focuses on direct investments across all stages—from seed and early-stage ventures to growth financing and mezzanine—primarily in biopharmaceuticals, medical devices, diagnostics, and related sectors, while also pursuing fund-of-funds strategies.[1][2] Its mission centers on achieving capital appreciation through a diversified portfolio of life sciences companies, with a strong emphasis on European opportunities, including public listings on Euronext Amsterdam via vehicles like LSP Life Sciences Fund N.V.[2] LSP has significantly impacted the startup ecosystem by backing over 75 portfolio companies, such as Ariceum Therapeutics, T-Knife, and Perfuze, fueling innovations in oncology, neurovascular tech, and cardiology, and raising massive funds like €1B in 2022.[5]
LSP traces its roots to 1988 in the Netherlands, emerging as a pioneer in European life sciences investing amid growing biotech momentum.[1] Key partners and management evolved through LSP Advisory B.V., which serves as the alternative investment fund manager (AIFM) and was fully acquired by EQT in 2021 for €450 million, marking a pivotal shift that bolstered its scale while retaining its Amsterdam base.[1][2] The firm's focus sharpened over decades from broad private equity to specialized life sciences direct investments and funds like LSP 4 and LSP Life Sciences Fund N.V. (established 2011), which targets listed European biopharma and medtech firms for milestone-driven value creation.[2][4] Early traction came from seed-to-late-stage bets, evolving into blockbuster funds, such as the €530M raise in recent years, solidifying LSP's independence until its EQT integration.[5]
LSP rides the surging wave of life sciences innovation, particularly in Europe, where biotech funding gaps persist amid U.S. dominance, timing its growth with post-pandemic R&D booms in oncology, neurotech, and diagnostics.[3][5] Market forces like milestone-driven value unlocks (e.g., partnerships, M&A) and Euronext listings favor its strategy, as seen in portfolios targeting biopharma and medtech amid aging populations and precision medicine trends.[2] By financing firms like Cardior and Perfuze, LSP influences the ecosystem, bridging startups to public markets and attracting mega-funds via EQT, thus elevating Europe's role in global health tech.[1][5]
LSP's EQT backing positions it for scaled deployments in AI-driven drug discovery and next-gen devices, with trends like regulatory tailwinds and cross-Atlantic M&A shaping aggressive growth.[1][5] Expect deeper Series B+ bets and fund expansions, evolving its influence from niche European player to global life sciences powerhouse, amplifying startup successes in a capital-scarce landscape. This builds on its foundational mission, turning science into scalable impact.[2][6]
